儿童鼻咽癌诱导化疗联合同步放化疗:ARAR0331研究结果
ARAR0331研究纳入111例IIb-IV期儿童鼻咽癌患者,接受3周期顺铂+氟尿嘧啶诱导化疗后同步放化疗。5年无事件生存率和总生存率分别为84.3%和89.2%,诱导化疗应答者放疗剂量可降至61.2 Gy。
要点
- 儿童鼻咽癌诱导化疗后同步放化疗5年EFS达84.3%、OS达89.2%。
- 诱导化疗应答者鼻咽及颈部放疗剂量可降至61.2 Gy。
核心结论
- 儿童鼻咽癌采用诱导化疗联合同步放化疗可获得优异结局。
- 对诱导化疗应答者降低放疗剂量是可行的。
- 同步放化疗减少顺铂周期数者5年EFS有下降趋势。
研究设计与样本
- 单臂前瞻性研究纳入111例IIb-IV期儿童鼻咽癌患者,中位年龄15岁,75例男性。
- 患者接受3周期顺铂+氟尿嘧啶诱导化疗,后行同步放化疗(顺铂3周期,后修订为2周期)。
- 诱导化疗完全或部分缓解者鼻咽及颈部放疗剂量为61.2 Gy,疾病稳定者为71.2 Gy。
主要发现
- 5年无事件生存率为84.3%,5年总生存率为89.2%。
- IIb、III、IV期5年无事件生存率分别为100%、82.8%、82.7%。
- 5年局部、远处及合并复发累积发生率分别为3.7%、8.7%、1.8%。
关键数值与推荐
- 诱导化疗方案:3周期顺铂+氟尿嘧啶。
- 同步放化疗方案:顺铂3周期(后修订为2周期)。
- 放疗剂量:诱导化疗应答者61.2 Gy,疾病稳定者71.2 Gy。
临床怎么用
- 儿童鼻咽癌可采用诱导化疗联合同步放化疗, outcomes优异。
- 对诱导化疗应答者考虑降低放疗剂量至61.2 Gy。
- 同步放化疗顺铂周期数减少可能影响无事件生存,需权衡。
局限性
- 研究为非随机单臂设计,同步放化疗顺铂周期数比较非预设随机。
- 样本量有限(111例),结论需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The treatment of childhood nasopharyngeal carcinoma has been adapted from adult regimens; pediatric-specific studies are limited. The ARAR0331 study sought to evaluate the impact of induction chemotherapy (IC) and concurrent chemoradiotherapy (CCR). PATIENTS AND METHODS: Patients with American Joint Committee on Cancer stages IIb to IV were scheduled to receive three cycles of IC with cisplatin and fluorouracil, followed by CCR with three cycles of cisplatin. Patients with complete or partial response to IC received 61.2 Gy to the nasopharynx and neck, and patients with stable disease received 71.2 Gy. RESULTS: Between February 2006 and January 2012, 111 patients (75 male) were enrolled. Median age was 15 years, and 46.8% of the patients were African American. After a feasibility analysis, the study was amended to reduce cisplatin to two cycles during CCR. The 5-year event-free survival (EFS) and overall survival estimates were 84.3% and 89.2%, respectively. The 5-year EFS for stages IIb, III, and IV were 100%, 82.8%, and 82.7%, respectively. The 5-year cumulative incidence estimates of local, distant, and combined relapse were 3.7%, 8.7%, and 1.8%, respectively. Patients treated with three versus two CCR cycles of cisplatin had improved 5-year postinduction EFS (90.7% v 81.2%, P = .14). CONCLUSION: Patients in ARAR0331 were characterized by advanced disease and by a high proportion of black children and adolescents. Treatment with IC and CRT resulted in excellent outcomes. A radiation dose reduction is possible for patients responding to IC. Although the outcomes are comparable, we observed a trend toward decreased EFS for patients assigned to receive fewer doses of cisplatin during CCR.
引用
- Rodriguez-Galindo C, Krailo MD, Krasin MJ, et al. Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study. J Clin Oncol. 2019. PMID: 31553639. doi:10.1200/JCO.19.01276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。